Ratings Alligator Bioscience AB

Equities

ATORX

SE0000767188

Market Closed - Nasdaq Stockholm Other stock markets 11:29:45 2024-05-28 am EDT			5-day change	1st Jan Change
0.956 ^SEK	-1.04%		+5.29%	+38.75%

May. 23	Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting	CI
May. 21	US FDA Grants Investigational New Drug Clearance for Alligator Bioscience's Late-stage Gastric Cancer Treatment Trial	MT

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Over the past four months, analysts' average price target has been revised downwards significantly.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ALLIGATOR BIOSCIENCE AB	+38.75%	69.01M	C+
MODERNA, INC.	+54.05%	63.85B	B-
IQVIA HOLDINGS INC.	-2.02%	41.83B	B
LONZA GROUP AG	+40.01%	40.47B	A
CELLTRION, INC.	-10.22%	27.17B	C
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B	B
BIO-TECHNE CORPORATION	+2.89%	12.73B	B+
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B	B+
MEDPACE HOLDINGS, INC.	+27.49%	12.07B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes